Evidence map›Paper›PMID 40731254›Full record

ArticleACS infectious diseases2025

GaSal-2: A Water-Soluble Antipseudomonal Agent Targeting the Extracellular Hemophore HasAp.

Aziza Frank, Lucia Hwang, William T Witt, Garrick Centola, Kieran Johnson, Yong Ai, Emel Sen-Kilic, Gage M Pyles, Annalisa B Huckaby, Catherine B Blackwood and 8 more

Abstract read
In one paragraph

Article in ACS infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Aziza FrankDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland 21201, United States.
Lucia HwangDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland 21201, United States.
William T WittWest Virginia University Vaccine Development Center, Department of Microbiology, Immunology and Cell Biology. Morgantown, West Virginia 26505, United States.
Garrick CentolaDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland 21201, United States.
Kieran JohnsonDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland 21201, United States.
Yong AiDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland 21201, United States.
Emel Sen-KilicWest Virginia University Vaccine Development Center, Department of Microbiology, Immunology and Cell Biology. Morgantown, West Virginia 26505, United States.
Gage M PylesWest Virginia University Vaccine Development Center, Department of Microbiology, Immunology and Cell Biology. Morgantown, West Virginia 26505, United States.
Annalisa B HuckabyWest Virginia University Vaccine Development Center, Department of Microbiology, Immunology and Cell Biology. Morgantown, West Virginia 26505, United States.
Catherine B BlackwoodWest Virginia University Vaccine Development Center, Department of Microbiology, Immunology and Cell Biology. Morgantown, West Virginia 26505, United States.
Sarah Jo MillerWest Virginia University Vaccine Development Center, Department of Microbiology, Immunology and Cell Biology. Morgantown, West Virginia 26505, United States.
S Matthew HudsonWest Virginia University Vaccine Development Center, Department of Microbiology, Immunology and Cell Biology. Morgantown, West Virginia 26505, United States.
Kellie HomDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland 21201, United States.
Wenbo YuDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland 21201, United States.
Alexander D MacKerellDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland 21201, United States.ORCID 0000-0001-8287-6804
Mariette BarbierWest Virginia University Vaccine Development Center, Department of Microbiology, Immunology and Cell Biology. Morgantown, West Virginia 26505, United States.
Angela WilksDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland 21201, United States.ORCID 0000-0002-0008-7690
Fengtian XueDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland 21201, United States.ORCID 0000-0002-4132-9887

Funding

Macromolecular Conformational HeterogeneityR35GM131710 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE · PI ALEXANDER D MACKERELL · 2019 to 2026
$6.2M
Pseudomonas aeruginosa heme sensing inhibitors targeting HasApR21AI161313 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI WILKS, ANGELA, XUE, FENGTIAN · 2021 to 2022
$425k
NIAID NIH HHS R21 AI161313NIGMS NIH HHS R35 GM131710
6 · The paper itself

Abstract

Multidrug-resistant

Indexed as

Anti-Bacterial AgentsBacterial ProteinsPseudomonas aeruginosaAnimalsBiofilmsHumansMicePseudomonas InfectionsAnti-Bacterial AgentsBacterial Proteinsbiofilmsextracellular hemophoregallium complexheme acquisitionPseudomonas aeruginosa

Identifiers

PMID40731254
PMCPMC12490196

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.